Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Exploring the Different COVID Tests

On this episode of HealthFirst Talks, host Grace Huang welcomes two medical expert guests to discuss the different COVID-19 tests, their efficacy, and what test to use in different scenarios. Those guests are Dr. Scott Cohen, Chief Medical Information Officer and Chief Performance Improvement Officer for Bassett Healthcare Network, and Dr. Fiona Collins, dentist and…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from HealthFirst on MarketScale.

Share

Get featured

Want MarketScale to feature Healthcare?

Book a 15-minute demo and we'll map your Healthcare expertise to the content buyers are searching for.

Book a demo

On this episode of HealthFirst Talks, host Grace Huang welcomes two medical expert guests to discuss the different COVID-19 tests, their efficacy, and what test to use in different scenarios. Those guests are Dr. Scott Cohen, Chief Medical Information Officer and Chief Performance Improvement Officer for Bassett Healthcare Network, and Dr. Fiona Collins, dentist and international speaker and author.

Drs. Cohen and Collins explained the two types of COVID-19 tests: PCR tests and antigen tests. “There are two broad types of COVID-19 diagnostic tests. The antigen test takes the nasal fluid and looks for the presence of the antigen. If so, it’s positive. The PCR is looking for the presence of coronavirus RNA,” Dr. Cohen said.

Which is more accurate? Dr. Collins explained, “When looking at accuracy, diagnostic tests can be high sensitivity or high specificity. With high sensitivity, you have very few false negatives. With high specificity, very few false positives.”

The doctors agreed that false negatives were more concerning for COVID-19. With a false positive, the worst that could happen is isolation. A false negative could lead to spread.

When looking at the two tests, Dr. Collins shared, “PCR tests have high specificity and sensitivity. Antigen is only high specificity. It can have a false-negative rate of 15-20%.”

With this in mind, PCR testing is clearly the stronger test, but it may not always be the best choice. For post-exposure testing, Collins said, “PCR is more reliable, but it will take a few days to get back, so patients should quarantine until results.”

In the case of mass testing, the antigen test may be better because it acts as a monitoring system, and people are being tested regularly. “Antigen testing is fastest and least expensive. No lab is needed. Because you’re regular testing, you can overcome the sensitivity issue,” Dr. Cohen added.

Learn more about COVID testing and precautions to take by watching the conversation.

HealthFirst

Part of this channel

HealthFirst

Practice-ready solutions for dental and medical offices nationwide.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

The Cost of Waiting: Why Healthcare Can't Afford Slow Decisions with Mark Van Sumeren

The Cost of Waiting: Why Healthcare Can't Afford Slow Decisions with Mark Van Sumeren

The healthcare industry faces significant consequences when delayed decision-making occurs. Prompt and efficient action is crucial to prevent adverse impacts on patient care and operational efficiency. Addressing this issue requires a commitment to more agile and informed decision processes.

  • 01Delayed decision-making in healthcare can lead to negative impacts on patient care and operational efficiency.
  • 02Healthcare organizations are encouraged to adopt agile decision-making processes to improve effectiveness.
  • 03Implementing informed and prompt decision-making strategies can mitigate the risks of inefficiencies and poor patient outcomes.

Aug 17, 2026

Medicare's ACCESS pilot is live, but patients can't find which providers offer it

Medicare's ACCESS pilot is live, but patients can't find which providers offer it

The Centers for Medicare & Medicaid Services (CMS) launched its tech-enabled chronic care pilot program, known as the ACCESS pilot. Despite its initiation, a significant issue persists as patients struggle to find which healthcare providers are participating in the program. Meanwhile, the FDA has authorized 115 AI-based medical devices in 2021.

  • 01CMS has initiated the ACCESS pilot program to enhance chronic care management using technology.
  • 02Patients are facing challenges in identifying healthcare providers involved in the ACCESS pilot.
  • 03In 2021, the FDA authorized 115 AI-based medical devices.

Aug 17, 2026

Sobi CEO Guido Oelkers named BioNTech's next chief executive, targeting multiple approved products by 2030

Sobi CEO Guido Oelkers named BioNTech's next chief executive, targeting multiple approved products by 2030

BioNTech has appointed Guido Oelkers, the current CEO of Sobi, as its next chief executive. Oelkers is tasked with advancing BioNTech's oncology pipeline to achieve multiple approved products by 2030.

  • 01BioNTech has selected Guido Oelkers as its new CEO, effective soon.
  • 02Guido Oelkers aims to turn BioNTech's deep oncology pipeline into several approved products by 2030.

Aug 17, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512